Breast Cancer, Hot Flash Due to Medication
Conditions
Brief summary
The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer. The objectives it aims to answer are: * To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer * To assess side effects of oxybutynin versus venlafaxine. * To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes. * To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer. Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total. Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.
Interventions
DRUGOxybutynin
Oxybutynin 5 mg twice per day for 6 weeks
DRUGVenlafaxine
Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
Sponsors
Reinier de Graaf Groep
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pre-, peri- or postmenopausal women of 18 years or above; * Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study; * Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.
Exclusion criteria
* Pregnant; * Breast feeding; * Patients who receive chemotherapy or immunotherapy/HER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period; * Palliative setting; * Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year; * Creatinine clearance \< 30 ml/min; * Liver cirrhosis; * Use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry; * Use of oxybutynin before study entry; * Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number and severity of hot flashes | 15 weeks total | Number and severity of hot flashes during 6-weeks of therapy measured by the Hot Flash Diary. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse effects of treatments | 15 weeks total | Adverse effects of treatments weekly measured by the National Cancer Institute Common Toxicity Criteria scale, version 5 |
| Sleep quality | 15 weeks total | Sleep quality at baseline and after 6 weeks of treatment measured by the Groningen Sleep Quality Scale (GSQ) |
| Anxiety and depression | 15 weeks total | Anxiety and depression measured at baseline and after 6 weeks of treatment with the Hospital Anxiety and Depression Scale (HADS) |
| Quality of life and health status | 15 weeks total | Quality of life and health status at baseline and after 6 weeks of treatment measured by the EORTC-QLQ-C30 |
| Cognitive function | 15 weeks total | Cognitive function measured at baseline and after 6 weeks of treatment with the 6-item cognitive impairment test (6-CIT) |
| Adherence | 15 weeks total | Ask patients the following question after 6 weeks of treatment: 'Would you like to continue the endocrine therapy for the recommended duration of therapy taking the current medication (oxybutynin or venlafaxine) given the number and severity of hot flashes you experience during the last week?' |
| Preference | 15 weeks total | Ask patients the following question after 6 weeks of the final treatment: 'Do you have a preference taking the medication from study period 1 or study period 2?' |
| Sexual function | 15 weeks total | Sexual function measured at baseline and after 6 weeks of treatment with the Sexual Activity Questionnaire (SAQ) |
Countries
Netherlands
Contacts
Primary ContactMarte Smits, MSc
Outcome results
None listed